DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category OCUL
http://www.ocutx.com/
Ocular Therapeutix (Nasdaq: $OCUL): Sanofi Rumor, AXPAXLI and the Real Takeover Logic Behind the Wet AMD Story
Ocular Therapeutix is back in focus after media reports linked Sanofi to a possible takeover approach. According to reports citing French publication La Lettre, Sanofi previously approached Ocular with an offer around $16 per share, Ocular’s board reportedly rejected that initial proposal, and Sanofi may be considering or preparing a higher bid. Neither Ocular Therapeutix nor Sanofi has confirmed a transaction, and that distinction matters. The confirmed foundation of the story is not the takeover rumor; it is AXPAXLI, Ocular’s investigational axitinib intravitreal hydrogel implant, which recently produced positive Phase 3 SOL-1 data in wet age-related macular degeneration.
Ocular Therapeutix (OCUL) in April 2026 (Updated april 14)
This April update picks up the OCUL story where our earlier Merlintrader pieces left it: from the pre-readout run-up and takeover chatter, through the February SOL-1 topline and the violent sell-the-news reaction, to the next regulatory, scientific and commercial steps that now matter most.
Ocular Therapeutix Inc ( $OCUL) Feb25 Update : superiority achieved, durability confirmed, what comes next
Phase 3 SOL-1 delivered the first statistically significant superiority versus an approved anti-VEGF in wet AMD, with year-long durability from a single injection and a clean safety profile. The market reaction has been volatile; the strategic picture for the next 24–36 months is clearer than the tape suggests.
Ocular Therapeutix Inc ($OCUL)
Positive 52-week SOL-1 data position AXPAXLI as a potential long-acting option versus aflibercept, yet the stock sells off as investors question trial design, real-world relevance and the regulatory path.
OCUL Ocular Therapeutix run-up Updated Feb 16 2026
Deep dive on Ocular Therapeutix: from DEXTENZA to the late-stage AXPAXLI retina franchise, with SOL-1 topline data in wet AMD coming in late February 2026 and a balance sheet funded into 2028.
OCUL Ocular Therapeutix Inc
Daily Hit on Ocular Therapeutix after the latest spike on renewed takeover chatter and ahead of the 52-week phase 3 SOL-1 readout for AXPAXLI (suprachoroidal axitinib). Cash-heavy balance sheet, a single pivotal asset at the centre of the story, and a market now trying to price both M&A optionality and binary clinical risk.